This page shows what was measured, who it was measured in, and what that does not settle.
What Telmisartan does in the body
Hypertension, to lower blood pressure
From the FDA-approved label: Angiotensin II is formed from angiotensin I in a reaction catalyzed by angiotensin-converting enzyme (ACE, kininase II). Angiotensin II is the principal pressor agent of the renin-angiotensin system, with effects that include vasoconstriction, stimulation of synthesis and release of aldosterone, cardiac stimulation, and renal reabsorption of sodium. Telmisartan blocks the vasoconstrictor and aldosterone-secreting effects of angiotensin II by selectively blocking the binding of angiotensin II to the AT 1 receptor in many tissues, such as vascular smooth muscle and the adrenal gland. Its action is therefore independent of the pathways for angiotensin II synthesis.
What happened in people
RNAWiki has not yet published a reviewed conclusion for this use.
§ A fixed RNAWiki sentence
Where this came from
Wording RNAWiki always uses, not a finding about this substance.
No reviewed claim names a result for any goal on this record.
No source is stored against this line.
The limit that matters most
Not recorded.
Where it acts
Not recorded.
Kind of result
No result is published, so no kind of result applies yet
Supervision
Professional supervision is normally required. A regulator classifies this substance in a way that restricts how it is supplied.
What the registries record it as
The substance registry classes this as chemical.
FDA substance registry · U5SYW473RQ · read 2026-08-29
Its recorded molecular formula is C33H30N4O2, weighing 514.63.
US prescribing information · a075633a-2a2a-4e88-8ede-b49a3920a16c · read 2026-08-30
Where each sentence above came from
No recorded sentence describes the change this makes in a way that stands on its own. The page opens with what it is taken for instead, and the recorded explanation follows below.
Shown as the opening line on this page.
No statement of the main limit is recorded.
The four opening statements run to 116 words.
Words this page uses
Four words worth knowing first
Chosen from what this page shows, with each one explained before the word it depends on.
Stand-in result
A stand-in result is a number measured because the real result takes too long.
A picture of it, and where the picture fails
It is like judging a journey by the speedometer rather than by arriving.
Where that stops being true. Speed does predict arrival. Many stand-in results do not predict the real one.
What people get wrong. A stand-in result is often reported as the result itself.
A surrogate endpoint substituted for a clinical endpoint, valid only where the substitution has been shown to hold.
Enzyme
An enzyme is a protein that speeds up one chemical change.
A picture of it, and where the picture fails
An enzyme is like a machine on a production line doing one cut.
Where that stops being true. A machine is switched on and off by a person. Enzymes are controlled by the cell.
What people get wrong. Enzymes are thought to be used up. They are not; they work again and again.
A catalytic protein that lowers the activation energy of a specific reaction.
Receptor
A receptor is a part of a cell that a signal fits into.
A picture of it, and where the picture fails
A receptor is like a lock waiting for one key.
Where that stops being true. A lock either opens or does not. A receptor can be half-triggered, or worn out.
What people get wrong. Fitting a receptor is read as causing a benefit. It causes a step, and nothing more.
A protein that binds a specific ligand and converts that binding into a cellular response.
Pathway
A pathway is a chain of steps inside a cell, each one setting off the next.
A picture of it, and where the picture fails
A pathway is like a row of dominoes.
Where that stops being true. Dominoes fall one way. Pathways loop back and can switch themselves off.
What people get wrong. Changing one step is read as changing the outcome. Other steps often absorb it.
An ordered series of molecular interactions producing a defined cellular change.
What happened in people◇Read from sources, not yet reviewed
What was measured, goal by goal
One row for each goal a registered study measured something for. One column for each kind of thing that could be measured.
Registered studies list 40 outcome measures that RNAWiki could read. A registered study says what someone planned to measure. It does not say what they found. 0 of the matched studies tested this substance, and 0 posted a result.
There is no single score. A strong test result and a weak life result are different facts.
Goals down the side, kinds of measurement across the top. Each cell says what kind of thing was registered, not what was found.
Goal
Life outcome
What a body can do
How a person feels
A test result
A step in the body
Harms
How long
Who was studied
Cholesterol
∅Nothing in the sources checkedNo registered study lists a life outcome for this goal.
∅Nothing in the sources checkedNo registered study lists a performance measure for this goal.
∅Nothing in the sources checkedNo registered study lists a symptom measure for this goal.
△Only a number moved4 registered test measure.
∅Nothing in the sources checkedNo registered study lists a body-step measure for this goal.
—Not recordedHarms were not a registered measure for this goal.
—Not recordedNo finished study window is recorded.
…Waiting for a reviewerWho was studied is listed further down the page.
Blood sugar
∅Nothing in the sources checkedNo registered study lists a life outcome for this goal.
∅Nothing in the sources checkedNo registered study lists a performance measure for this goal.
∅Nothing in the sources checkedNo registered study lists a symptom measure for this goal.
△Only a number moved3 registered test measure.
∅Nothing in the sources checkedNo registered study lists a body-step measure for this goal.
—Not recordedHarms were not a registered measure for this goal.
—Not recordedNo finished study window is recorded.
…Waiting for a reviewerWho was studied is listed further down the page.
Healthy ageing
…Waiting for a reviewer1 registered study measure of this kind. No reviewed result yet.
∅Nothing in the sources checkedNo registered study lists a performance measure for this goal.
∅Nothing in the sources checkedNo registered study lists a symptom measure for this goal.
∅Nothing in the sources checkedNo registered study lists a test result for this goal.
∅Nothing in the sources checkedNo registered study lists a body-step measure for this goal.
—Not recordedHarms were not a registered measure for this goal.
—Not recordedNo finished study window is recorded.
…Waiting for a reviewerWho was studied is listed further down the page.
Which registered measures put each goal on this table
Cholesterol
metabolic profiles including lipid profile and blood glucose; control of blood pressure and decline in triglycerides level; triglycerides; diastolic blood pressure change in ldl cholesterol
Blood sugar
metabolic profiles including lipid profile and blood glucose; insulin resistance; insulin sensitivity
Healthy ageing
mortality
Sorted by fixed word lists, version v1. A name the rules do not recognise stays unsorted rather than moving to the nearest column.
What each mark on this table means
∅ Nothing in the sources checked
No registered study lists a life outcome for this goal.
△ Only a number moved
4 registered test measure.
— Not recorded
Harms were not a registered measure for this goal.
… Waiting for a reviewer
Who was studied is listed further down the page.
What happened in people◇Read from sources, not yet reviewed
What happened in people
Each card is one study: the exact question it asked, who was in it, and whether it showed what it set out to show.
ONTARGET. Composite Endpoint of Cardiovascular Death, Non-fatal Myocardial Infarction, Non-fatal Stroke and Hospitalization for Congestive Heart Failure
✗ The study did not show it
Who was studied
NCT00153101
How many people
31546
Study design
Phase 4
Compared against
Not recorded for this study
Kind of result
Living longer, or avoiding a major event
What was found
Result not recorded on this page
Repeated elsewhere
Unreplicated
What this does not prove. A study that did not show an effect does not show that no effect exists anywhere.
The limits of this study, and where it came from
Main limit. No limitation is recorded for this study.
How far it carries. This study is recorded from the curated record, not from the registry match.
Form and route. Oral
Interval reported. Not recorded in this summary
Written into the record, not signed off as a reviewed claim.
openFDA Drugs@FDA · a recorded source, not a stored snapshot
openFDA NDC Directory · a recorded source, not a stored snapshot
openFDA SPL label · a recorded source, not a stored snapshot
PubChem PUG-REST · a recorded source, not a stored snapshot
To evaluate the impact of circadian time of treatment in cardiovascular, cerebrovascular, metabolic, and renal risk assessment.
✗ The study did not show it
Who was studied
NCT00741585
How many people
21983
Study design
Phase 4
Compared against
Not recorded for this study
Kind of result
A number that stands in for health
What was found
Result not recorded on this page
Repeated elsewhere
Unreplicated
What this does not prove. A study that did not show an effect does not show that no effect exists anywhere.
The limits of this study, and where it came from
Main limit. No limitation is recorded for this study.
How far it carries. This study is recorded from the curated record, not from the registry match.
Form and route. Oral
Interval reported. Not recorded in this summary
Written into the record, not signed off as a reviewed claim.
openFDA Drugs@FDA · a recorded source, not a stored snapshot
openFDA NDC Directory · a recorded source, not a stored snapshot
openFDA SPL label · a recorded source, not a stored snapshot
PubChem PUG-REST · a recorded source, not a stored snapshot
Number of Patients With First Recurrent Stroke of Any Type, Fatal or Nonfatal (Antiplatelet Comparison Only)
✗ The study did not show it
Who was studied
NCT00153062
How many people
20332
Study design
Phase 4
Compared against
Not recorded for this study
Kind of result
A number that stands in for health
What was found
Result not recorded on this page
Repeated elsewhere
Unreplicated
What this does not prove. A study that did not show an effect does not show that no effect exists anywhere.
The limits of this study, and where it came from
Main limit. No limitation is recorded for this study.
How far it carries. This study is recorded from the curated record, not from the registry match.
Form and route. Oral
Interval reported. Not recorded in this summary
Written into the record, not signed off as a reviewed claim.
openFDA Drugs@FDA · a recorded source, not a stored snapshot
openFDA NDC Directory · a recorded source, not a stored snapshot
openFDA SPL label · a recorded source, not a stored snapshot
PubChem PUG-REST · a recorded source, not a stored snapshot
All-cause mortality
✗ The study did not show it
Who was studied
NCT02735707
How many people
20000
Study design
Phase 3
Compared against
Not recorded for this study
Kind of result
Living longer, or avoiding a major event
What was found
Result not recorded on this page
Repeated elsewhere
Unreplicated
What this does not prove. A study that did not show an effect does not show that no effect exists anywhere.
The limits of this study, and where it came from
Main limit. No limitation is recorded for this study.
How far it carries. This study is recorded from the curated record, not from the registry match.
Form and route. Oral
Interval reported. Not recorded in this summary
Written into the record, not signed off as a reviewed claim.
openFDA Drugs@FDA · a recorded source, not a stored snapshot
openFDA NDC Directory · a recorded source, not a stored snapshot
openFDA SPL label · a recorded source, not a stored snapshot
PubChem PUG-REST · a recorded source, not a stored snapshot
The primary study outcomes are composite of non-fatal stroke, non-fatal myocardial infarction and cardiovascular death.
✗ The study did not show it
Who was studied
NCT01011660
How many people
13542
Study design
Phase 4
Compared against
Not recorded for this study
Kind of result
Living longer, or avoiding a major event
What was found
Result not recorded on this page
Repeated elsewhere
Unreplicated
What this does not prove. A study that did not show an effect does not show that no effect exists anywhere.
The limits of this study, and where it came from
Main limit. No limitation is recorded for this study.
How far it carries. This study is recorded from the curated record, not from the registry match.
Form and route. Oral
Interval reported. Not recorded in this summary
Written into the record, not signed off as a reviewed claim.
openFDA Drugs@FDA · a recorded source, not a stored snapshot
openFDA NDC Directory · a recorded source, not a stored snapshot
openFDA SPL label · a recorded source, not a stored snapshot
PubChem PUG-REST · a recorded source, not a stored snapshot
the prevention of recurrent stroke.
✗ The study did not show it
Who was studied
NCT01198496
How many people
5000
Study design
Phase 4
Compared against
Not recorded for this study
Kind of result
A number that stands in for health
What was found
Result not recorded on this page
Repeated elsewhere
Unreplicated
What this does not prove. A study that did not show an effect does not show that no effect exists anywhere.
The limits of this study, and where it came from
Main limit. No limitation is recorded for this study.
How far it carries. This study is recorded from the curated record, not from the registry match.
Form and route. Oral
Interval reported. Not recorded in this summary
Written into the record, not signed off as a reviewed claim.
openFDA Drugs@FDA · a recorded source, not a stored snapshot
openFDA NDC Directory · a recorded source, not a stored snapshot
openFDA SPL label · a recorded source, not a stored snapshot
PubChem PUG-REST · a recorded source, not a stored snapshot
What we know
RNAWiki holds 6 written-up human studies for this substance, each with the question it asked.
How we know it
Each card names the study, the number of people and what the study set out to measure.
What this does not prove
These summaries were written by a person and have not been signed off as reviewed claims.
Why it matters
A study that failed is as informative as one that worked, and both are here.
What we still do not know
No reviewed claim exists, so no exact population, effect size or interval is published yet.
What happened in people◇Read from sources, not yet reviewed
How close this is to real life
The top step is something a person would feel or care about. The bottom is a guess from software. Filled steps are where evidence exists for this substance.
■Living longer, or avoiding a major eventEvidence recorded. Death, a heart attack, a stroke, a hospital stay.3 registered measures of this kind. 2 written-up studies measured this and did not show a benefit.
□What a body can do day to dayNo evidence recorded. Walking, dressing, breathing, recovering.No registered study measures this.
□Measured performanceNo evidence recorded. How much was lifted, how far was run, how fast.No registered study measures this.
□Symptoms and quality of lifeNo evidence recorded. Pain, tiredness, mood, sleep, as the person rated it.No registered study measures this.
■A number that stands in for healthEvidence recorded. Cholesterol, blood sugar, bone density. A stand-in, not the thing itself.22 registered measures of this kind.
■A step measured inside a personEvidence recorded. Something measured in human tissue or human cells.A human record sits on the stored organism ladder.
■AnimalsEvidence recorded. Mice, rats, dogs. Useful for ideas, not proof about people.Stored records in Mouse, Rat. A result in animals says what to test next. It does not say what happens in people.
■Cells in a dishEvidence recorded. Cells or chemistry on a bench, far from a whole body.Stored mechanism abstracts describe steps measured in cells or tissue.
□A guess from softwareNo evidence recorded. Nobody measured it. RNAWiki never publishes one as a finding.RNAWiki stores no prediction for this record. Software can suggest a link. RNAWiki does not publish one as a finding.
Higher on these steps means closer to something a person would feel. It does not mean better done.
What it would be like to take◇Read from sources, not yet reviewed
Felt, measured, or meaningful
Three different things that get called the same word. Registered studies measured all three, and mixing them is how a blood test becomes a health claim.
Felt
Things a person could notice without a test.
No registered study measured anything of this kind.
Measured
Things only a test, a scale or a device shows.
supine diastolic blood pressure at trough
home blood pressure in the early morning
blood pressure surge in the morning
blood pressure
metabolic profiles including lipid profile and blood glucose
high sensitivity c reactive protein
trough seated systolic blood pressure at week 8
seated trough cuff systolic blood pressure to week 7
control of blood pressure and decline in triglycerides level
insulin resistance
and 12 more.
Meaningful
Things that change how a life goes, not only a number.
first recurrent stroke of any type fatal or nonfatal
prevention of recurrent stroke
mortality
A registered study says what someone planned to measure. It does not say what they found. A number moving is not the same as a life going better. The two are shown apart here.
Felt, but not shown to help. A person notices a change. No study showed it leads anywhere good.
Measured, but not felt. A number moves. The person notices nothing. Both can be true.
Measured, but not shown to matter. A number moves in the good direction. Nobody showed that lives went better.
Matters, but takes years. The result that counts may take longer than anyone would keep watching.
Names that fit none of the three (15)
after one year of treatment in proteinuria
glomerular filtration rate gfr after five years of treatment
at 8 weeks in seated trough cuff mean dbp
seated trough cuff mean dbp
study a annual change in total kidney volume
incidence of adverse events
changes in electrocardiogram
homa index
il 6
efficacy
visceral adipose tissue volume
auc0 tz
cmax
recurrence of atrial fibrillation
part b auc cmax of chlorthalidone
These are harms, study-process measures, or names the rules did not recognise. They are shown rather than dropped.
What it would be like to take◇Read from sources, not yet reviewed
How long anything takes
Nine different lengths of time that get confused with each other. None of them is worked out from another.
Before anything is noticed.RNAWiki does not store this separately, and never works it out from another figure on this page.
Before a test result moves.RNAWiki does not store this separately, and never works it out from another figure on this page.
Before performance moves.RNAWiki does not store this separately, and never works it out from another figure on this page.
How long the result was watched.No finished study window is recorded for a study that tested this substance.
How long people took it.How long people actually took it is not stored. The study window is not the same thing.
How long people were followed.Follow-up length is not stored separately. It is never read off the study window, which would be a different thing.
How fast the body clears it. 24 hours hours
Read from the label, which states: “Telmisartan shows bi-exponential decay kinetics with a terminal elimination half-life of approximately 24 hours.”
How long effects linger.RNAWiki does not store this separately, and never works it out from another figure on this page.
Beyond the studies. Nothing is recorded about the long term.
The longest finished study sets the edge of what anyone measured.
A study window is not how long people took it, and neither is how long they were followed. Where RNAWiki holds only one of the three, it shows one.
What is missing or unclear◇Read from sources, not yet reviewed
Were people like you studied?
RNAWiki cannot tell whether a study fits you. It can show who was in it, and where the result stops carrying.
Who was studied
People similar to this profile were included.
Telmisartan is an angiotensin II receptor blocker (ARB) indicated for: • Treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions.( 1.1 ) • Cardiovascular (CV) risk reduction in patients unable to take ACE inhibitors (1.2) 1.1 Hypertension Telmisartan tablets,USP are indicated for the…
Who is missing from the studies
Which groups were under-represented in the studies has not been recorded for this substance. Pregnancy, breastfeeding, children, older adults, and people with liver or kidney conditions are commonly excluded from trials; nothing here says whether they were.
What the label states about particular groups
On pediatric, the label states: “Safety and effectiveness in pediatric patients have not been established [ see Clinical Pharmacology ( 12.3) ].”
US prescribing information · a075633a-2a2a-4e88-8ede-b49a3920a16c · read 2026-08-30
On older people, the label states: “Of the total number of patients receiving telmisartan in hypertension clinical studies, 551 (19%) were 65 to 74 years of age and 130 (4%) were 75 years or older.”
US prescribing information · a075633a-2a2a-4e88-8ede-b49a3920a16c · read 2026-08-30
On people who are pregnant, the label states: “Risk Summary Telmisartan can cause fetal harm when administered to a pregnant woman.”
US prescribing information · a075633a-2a2a-4e88-8ede-b49a3920a16c · read 2026-08-30
On people who are breastfeeding, the label states: “Risk Summary There is no information regarding the presence of telmisartan in human milk, the effects on the breastfed infant, or the effects on milk production.”
US prescribing information · a075633a-2a2a-4e88-8ede-b49a3920a16c · read 2026-08-30
Where the result stopped carrying
This is a scope explorer, not a diagnosis engine.
It shows who was studied so you can see whether people similar to you were included.
RNAWiki cannot tell whether a study fits you. It can show who was in it.
What it would be like to take◇Read from sources, not yet reviewed
Why it might seem to do nothing
A real effect and a noticed effect are different things. These are the recorded reasons the two come apart.
It was studied for a different goal
The studies measured something else entirely.
On this record: Some registered studies measured things that match no goal on this page.
It was studied in different people
The people in the studies were not much like the reader.
On this record: Which groups were under-represented in the studies has not been recorded for this substance. Pregnancy, breastfeeding, children, older adults, and people with liver or kidney conditions are commonly excluded from trials; nothing here says whether they were.
The evidence may simply be wrong
Small early studies often do not hold up.
On this record: RNAWiki has not yet published a reviewed conclusion for this use.
Other reasons RNAWiki checked and found nothing for (10)
A different form was studied
The studied form is not the form on the shelf. Nothing in this record points to this reason.
There was nothing to correct
Where a level is already normal, topping it up may change nothing. Nothing in this record points to this reason.
Something else had to happen too
In the studies it was paired with training, a diet or another treatment. Nothing in this record points to this reason.
The change is too small to feel
A real change can still sit below what a person notices. Nothing in this record points to this reason.
Day-to-day swing hides it
Sleep, food, stress and time of day move most numbers more than this would. Nothing in this record points to this reason.
Not enough time yet
The studies ran longer than the person has waited. Nothing in this record points to this reason.
It was not taken as studied
Missed days change the result, and studies count them. Nothing in this record points to this reason.
Something else changed at the same time
Two changes at once cannot be told apart afterwards. Nothing in this record points to this reason.
The product may not be what it says
Contents of a sold product are not always what the label states. Nothing in this record points to this reason.
No recorded reason
RNAWiki has nothing stored that would explain it. Nothing in this record points to this reason.
None of these is a reason to take more. Taking more is not a step this page ever suggests.
What it would be like to take◇Read from sources, not yet reviewed
What taking it involves
The recorded facts about getting hold of it and using it. Nothing here is a suggestion about what you should do.
How it is supplied
Prescription only
❝ Quoted from a source
Where this came from
Copied from a source RNAWiki stored, with the source named.
Read from the recorded approval status.
No source is stored against this line.
Form and route
Oral
✎ Source-linked record
Where this came from
A person wrote this into the record with the study named beside it. No reviewer has signed it off.
The form and route recorded on this substance.
No source is stored against this line.
Who oversees it
Professional supervision is normally required. A regulator classifies this substance in a way that restricts how it is supplied.
❝ Quoted from a source
Where this came from
Copied from a source RNAWiki stored, with the source named.
Suppression classes recorded: S3, S6.
No source is stored against this line.
What is in the pack
Sold as tablet, given by the oral route.
✎ Source-linked record
Where this came from
A person wrote this into the record with the study named beside it. No reviewer has signed it off.
Recorded notes on how this is sold and what that means for what is in the pack.
No source is stored against this line.
Where it is registered
Regulatory records are listed in the technical disclosure at the foot of this page.
# Counted from records
Where this came from
A count of rows RNAWiki holds. It describes our records, not your body.
Register entries are stored per jurisdiction and shown with their dates.
No source is stored against this line.
Why people stop
Not recorded.
∅ Nothing recorded
Where this came from
RNAWiki holds nothing here and says so rather than guessing.
No record of why people stopped taking it is stored for this substance.
No source is stored against this line.
What it would be like to take∅Nothing found in the sources checked
What can go wrong
Sorted by where each line came from. A regulator's label and a report somebody sent in are not the same kind of fact.
∅Nothing found in the sources checked
No harm is recorded against this substance in the sources RNAWiki checked. Finding nothing is not the same as showing there is nothing.
The sources listed were searched and held nothing. That is not the same as nothing existing.
Reports sent to a regulator
These are reports people sent to a regulator. They do not show the medicine caused the reaction.
Nobody counted how many people took the medicine and reported nothing.
The same event can be reported more than once, and many reports are incomplete.
News coverage, lawsuits and new warnings change how often people report.
A count is not a rate and not a risk.
Telmisartan appears in spontaneous reports to regulators. Across the 10 most-reported reaction terms, 1568 reaction mentions were counted. One report can name several reactions.
The recorded terms (10)
hypotension — 233 reaction mentions
hyponatraemia — 219 reaction mentions
acute kidney injury — 168 reaction mentions
hypertension — 165 reaction mentions
blood pressure increased — 162 reaction mentions
hyperkalaemia — 159 reaction mentions
loss of consciousness — 129 reaction mentions
renal failure acute — 129 reaction mentions
renal failure — 111 reaction mentions
suicide attempt — 93 reaction mentions
open-targets-adr · recorded 2026-06-24 · a recorded source, not a stored snapshot
Over a long time. No completed tested study window is recorded, so long-term effects are not established by the registry record.
Groups the studies covered thinly. Which groups were under-represented in the studies has not been recorded for this substance. Pregnancy, breastfeeding, children, older adults, and people with liver or kidney conditions are commonly excluded from trials; nothing here says whether they were.
What is missing or unclear◇Read from sources, not yet reviewed
Does the exact form matter?
Evidence belongs to the exact thing that was tested. A different salt, a different mixture or a different preparation is a different question.
The form that was studied
Oral
✎ Source-linked record
Where this came from
A person wrote this into the record with the study named beside it. No reviewer has signed it off.
The form used in the studies cited on this page.
No source is stored against this line.
What is sold
Not recorded.
∅ Nothing recorded
Where this came from
RNAWiki holds nothing here and says so rather than guessing.
Nothing further is recorded about which forms are sold.
No source is stored against this line.
What is recorded as being sold
152 products list this as an active ingredient in the United States drug directory. 106 of them contain it and nothing else.
FDA National Drug Code directory · 72162-2438 · read 2026-08-29
They are sold as granule, powder and tablet, taken oral.
FDA National Drug Code directory · 72162-2438 · read 2026-08-29
The regulator's established pharmacologic class for it is angiotensin 2 receptor antagonists [moa] and angiotensin 2 receptor blocker [epc].
FDA National Drug Code directory · 72162-2438 · read 2026-08-29
55 published labels name it as an active ingredient. 42 of them describe this substance alone, which is where its own label text on this page comes from.
US prescribing information · 2e3cc412-fa44-4304-aabc-d6e412f81fbf · read 2026-08-29
Those labels are classed as human prescription drug.
US prescribing information · 2e3cc412-fa44-4304-aabc-d6e412f81fbf · read 2026-08-29
Telmisartan is oral at 3 DOSAGE FORMS AND STRENGTHS • 20 mg, white to off-white, round shaped, uncoated tablet, debossed with "C44" on one side and plain on other side. • 40 mg, white to off-white, oblong, biconvex, uncoated tablet, debossed…, recorded as fda label in effect 2023-09-30 in the United States.
US prescribing information · a075633a-2a2a-4e88-8ede-b49a3920a16c · read 2026-08-30
Recorded price in US: 0.10387–0.15626 USD per one unit as the pricing file counts it — a tablet, capsule, patch or single item, across 62 priced products whose strengths and pack forms differ, as of 2026-08-26, paid by retail pharmacies buying the product, as surveyed by the Centers for Medicare & Medicaid Services. It is not a list price, an insurance price, or what anyone pays at a counter..
Recorded source · 2026-08-26 · read 2026-08-28
Evidence carries across two names for one substance. It does not carry across a salt, a mirror form or a mixture.
What it would be like to take◇Read from sources, not yet reviewed
What you could measure
This one is decided with a clinician, so this section holds questions to ask rather than a plan to run.
Self-experiment planning is not offered for a prescription or clinician-supervised medicine. The questions below are for a clinician or pharmacist.
Questions worth asking
Which of the trials of Telmisartan studied people like me?
What was measured, and for how long?
Was the result a laboratory value or a health outcome?
What would we watch for, and when would we stop?
Tracking can show whether something changed for you. It cannot show what caused it.
RNAWiki records evidence. It does not say whether this substance is right for you.
What is missing or unclear◇Read from sources, not yet reviewed
What nobody knows yet
Open questions, each with why it is open and what would close it.
Missing populations
Which groups were under-represented in the studies has not been recorded.
Why it matters. Recorded by the evidence model as a gap on this record.
What would answer it
A study that measures it, and a reviewer to sign it off.
Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.
Missing long-term data
No completed tested study window is recorded.
Why it matters. Recorded by the evidence model as a gap on this record.
What would answer it
A study that measures it, and a reviewer to sign it off.
Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.
No reviewed conclusion
RNAWiki has not yet published a reviewed conclusion for this use.
Why it matters. Recorded by the evidence model as a gap on this record.
What would answer it
A study that measures it, and a reviewer to sign it off.
Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.
Missing interaction studies
No interaction was found in the registers checked. Not finding one is not the same as showing there is none.
Why it matters. Recorded by the evidence model as a gap on this record.
What would answer it
A study that measures it, and a reviewer to sign it off.
Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.
Formulation uncertainty
Several salts, forms or products of Telmisartan are recorded. Results from one form may not transfer to another.
Why it matters. Recorded by the evidence model as a gap on this record.
What would answer it
A study that measures it, and a reviewer to sign it off.
Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.
Mechanism not reviewed
No reviewed mechanism story exists for this substance.
Why it matters. Recorded by the evidence model as a gap on this record.
What would answer it
A study that measures it, and a reviewer to sign it off.
Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.
What happened in people◇Read from sources, not yet reviewed
Check any of this yourself
Every line above traced back to the study it came from. This is the technical layer, and the vocabulary changes here.
How many documents were read
41 documents were read for this substance.
RNAWiki source record
38 of them state the same halfLife, and they agree.
RNAWiki source record
41 of them state the same bioavailability, and they agree.
RNAWiki source record
41 of them state the same tMax, and they agree.
RNAWiki source record
41 of them state the same proteinBinding, and they agree.
RNAWiki source record
Where else this substance is registered
FDA substance identifier (UNII)
U5SYW473RQ
RxNorm concept
205304
Checks this page had to pass
✓ Passed
Identity resolved
no open identity hold
✓ Passed
No unresolved merge across substance families
no quarantine open
✓ Passed
Every public sentence names a source
The opening statement carries the origin: Written into the record, not signed off.
✗ Not passed
Trial roles classified for highlighted evidence
No registered study is classified as testing this substance.
✓ Passed
No internal keys in reader text
enforced by the copy-contract test over the rendered page
✓ Passed
Safety mode resolved
Suppression classes recorded: S3, S6.
✓ Passed
Canonical metadata present
slug and display name present
What is missing or unclear◇Read from sources, not yet reviewed
How this medicine reached us
Kept near the foot of the page. A historical event moves up only when it changes something about this substance today.
What the approval register records
37 approved applications cover products containing this substance. The earliest was NDA020850, approved 19981110 to BOEHRINGER INGELHEIM.
This order is fixed in code and does not count clicks or time on the page.
What is not here
5 questions this page could not answer
These sections were prepared and left out because there was nothing to put in them. They are listed rather than hidden, so the gaps in this record are visible.
The path through the body — found nothing in the sources checked.
What it may clash with — found nothing in the sources checked.
Other ways to the same goal — found nothing in the sources checked.
Claims that go past the evidence — found nothing in the sources checked.
What changed on this page — found nothing in the sources checked.
The record as stored
The full record, for auditing
Everything above is built from what is below. This layer keeps the technical vocabulary, record identifiers and every stored row, so a reader who wants to check the page can.
Recorded evidence blocks (14)
Q2
What did Telmisartan's largest trial (1165781 people) and its longest (19 years) measure?
1165781 people in Telmisartan's largest registered study, 19 years in its longest registered window, measuring ONTARGET. 3-fold Composite Endpoint of Doubling of Serum Creatinine, Progression to End Stage Renal Disease (ESRD) and All-cause Mortality in Diabetic Nephropathy Patients. ClinicalTrials.gov · 2026-09-01
50 phase4, 39 phase1, 39 phase3, 35 na or unstated, 23 phase2, 11 na, 1 early phase1; NCT07652567; 2026-04-30. Last human test completed 2026, NCT07652567.
Interpretation These counts include studies where Telmisartan was a comparison treatment, a background treatment or an exposure in an observational study, and the longest window may be a planned end date. Trial roles have not yet been classified for this record.
Show the evidence
phase4
50
phase1
39
phase3
39
na or unstated
35
phase2
23
na
11
2 more recorded rows
early phase1
1
Last recorded human testNCT07652567
2026-04-30
recorded 2026-09-01 · last checked 2026-09-04
Q3
From mouse to human: where has Telmisartan shown lifespan?
ONTARGET. 3-fold Composite Endpoint of Doubling of Serum Creatinine, Progression to End Stage Renal Disease (ESRD) and All-cause Mortality in Diabetic… — the recorded outcome words.
Show the evidence
mouse
mechanism-only
rat
mechanism-only
humanNCT00153101
lifespan; ONTARGET. 3-fold Composite Endpoint of Doubling of Serum Creatinine, Progression to End Stage Renal Disease (ESRD) and All-cause Mortality in Diabetic Nephropathy Patients; 193
recorded 2026-09-01 · last checked 2026-09-04
Q4
15 of Telmisartan's trials stopped: futility/efficacy, accrual/recruitment, funding/business, other?
futility/efficacy (2), accrual/recruitment (6), funding/business (1) and other (6): Telmisartan's stop wording, clustered. ClinicalTrials.gov · 2026-09-01
"Primary investigator moved to different university"; 15 of 193 registered studies
Show the evidence
Trial
NCT00185705
terminated; "Primary investigator moved to different university"
NCT00559286
terminated; "logistic reasons, patients could not be recruited"
NCT00863980
terminated; "Principle investigator resigned in 2013"
NCT01202721
terminated; "Terminated early due to lack of study feasibility and poor patient recruitment"
NCT02085265
terminated; "Lack of recruitment."
NCT02338232
terminated; "Lack of Accrual"
9 further recorded trials
NCT02968160
terminated; "Due to poor enrollment rate"
NCT03504566
withdrawn; "Registered and published incorrectly"
NCT03868839
terminated; "Lack of funding"
NCT04021550
withdrawn; "Covid-19 Pandemic prevented this study from beginning"
NCT04359953
terminated; "difficulty in recruiting"
NCT04360551
terminated; "Decrease in COVID-19 cases locally"
NCT04606563
terminated; "DSMC recommendation due to futility"
NCT04715763
terminated; "Poor recruitment due to decrease in COVID-19 rates locally"
NCT06483789
suspended; "Recruitment paused for Data Monitoring Committee (DMC) to review interim analysis data."
recorded 2026-09-01 · last checked 2026-09-04
Q5
Human studies of Telmisartan used Telmisartan 40 mg/HCTZ 12.5 mg — over how long?
20 recorded entries; human; capsule; also "Telmisartan 40 mg/HCTZ 12.5 mg", "Telmisartan 40 mg", "Telmisartan capsule 40 mg"
Show the evidence
human
NCT00144222
Telmisartan 40 mg/HCTZ 12.5 mg
NCT00144222
Telmisartan 40 mg
NCT00153088
capsule; Telmisartan capsule 40 mg
NCT00153088
capsule; Telmisartan capsule 80 mg
NCT00274144
telmisartan 40 mg
NCT00281580
Telmisartan 20 mg
14 more recorded rows
humanNCT00281580
Telmisartan 80 mg
humanNCT00326768
Telmisartan 80 mg/HCTZ 12.5 mg
humanNCT00421863
Micardis 80 mg
humanNCT00863980
Micardis Tablets 40mg
humanNCT01050062
Telmisartan 80mg
humanNCT01050062
Telmisartan 40mg
humanNCT01202721
Micardis 40/80 mg
humanNCT01286558
40 mg telmisartan
humanNCT01286558
80 mg telmisartan
humanNCT01356017
Telmisartan 80mg, S-amlodipine 5mg
humanNCT01356017
Micardis 80mg, Anydipine S 5mg
humanNCT01356017
Micardis 80mg
humanNCT02087540
Placebo(for Telmisartan 80mg)
humanNCT02231788
Telmisartan/S-Amlodipine 40/2.5mg
recorded 2026-09-01 · last checked 2026-09-04
Q6
Telmisartan's half-life is 24 hours — which schedules were studied?
24 hours, the half-life Telmisartan's label states. openfda-label · 57da6ef2-2e86-4e4d-90df-73a2a8cf97f6 · 2026-08-30
bioavailability 42% %.
Show the evidence
half life
24 hours hours; Telmisartan shows bi-exponential decay kinetics with a terminal elimination half-life of approximately 24 hours.
bioavailability
42% %; At 40 mg and 160 mg, the bioavailability was 42% and 58%, respectively.
metabolism
Metabolism and Elimination Following either intravenous or oral administration of 14 C-labeled telmisartan, most of the administered dose (>97%) was eliminated unchanged in feces via biliary excretion; only minute amounts were found in the urine (0.91% and 0.49% of total radioactivity, respectively).
recorded 2026-08-30 · last checked 2026-09-04
Q7
Which of 24 h mean diastolic blood pressure, 24 h mean systolic blood pressure and after one year of treatment in proteinuria did Telmisartan's trials measure?
24 h mean diastolic blood pressure, 24 h mean systolic blood pressure and after one year of treatment in proteinuria lead 40 outcome terms across Telmisartan's trials. ClinicalTrials.gov · 2026-09-01
glomerular filtration rate gfr after five years of treatment, at 8 weeks in seated trough cuff mean dbp, seated trough cuff mean dbp, study a annual change in total kidney volume, home blood pressure in the early morning and incidence of adverse events follow.
Show the evidence
supine diastolic blood pressure at trough
1
first recurrent stroke of any type fatal or nonfatal
1
after one year of treatment in proteinuria
1
glomerular filtration rate gfr after five years of treatment
1
at 8 weeks in seated trough cuff mean dbp
1
seated trough cuff mean dbp
1
14 more recorded rows
study a annual change in total kidney volume
1
home blood pressure in the early morning
1
incidence of adverse events
1
changes in electrocardiogram
1
homa index
1
blood pressure surge in the morning
1
blood pressure
1
metabolic profiles including lipid profile and blood glucose
1
il 6
1
high sensitivity c reactive protein
1
trough seated systolic blood pressure at week 8
1
efficacy
1
seated trough cuff systolic blood pressure to week 7
1
control of blood pressure and decline in triglycerides level
1
recorded 2026-09-01 · last checked 2026-09-04
Q8
Which of Telmisartan's 8 ongoing trials reports first?
All-cause mortality; Tolerability of oral telmisartan; latest 2033-03-01
Show the evidence
Trial
NCT02735707
"Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia"; n 20000; "All-cause mortality"; 2028-02
NCT06168487
"Telmisartan in Prostate Cancer"; n 36; "Tolerability of oral telmisartan"; 2027-04-01
NCT06815497
"Telmisartan in Combination With Cytotoxic Regimens in Platinum-Resistant Ovarian Cancer"; n 33; "Progression free survival"; 2029-05-14
NCT07207057
"Edmond J. Safra Accelerating Clinical Trials in Parkinson's Disease: A Multiarm Multi-stage Platform Trial"; n 1200; "Movement Disorder Society-Sponsored Revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Parts I and II combined"; 2031-07-31
NCT07370506
"Telmisartan for Prevention of Doxorubicin-Induced Cardiotoxicity in Breast Cancer Patients"; n 36; "Change in Left Ventricular Ejection Fraction (LVEF)"; 2027-02
NCT07547878
"Rapid and Simultaneous Initiation of Four Guideline-Directed CKD Therapies (RAPID-CKD)"; n 64; "On-study retention rate at 6 months"; 2029-03-31
2 further recorded trials
NCT07568574
"Impact of Medically Supervised Performance-Enhancing Substances (PES) on Elite Athletes"; n 60; "The incidence and severity of Treatment-related adverse events (TRAEs), including adverse events (AEs) and serious adverse events (SAEs), as assessed by the study physicians from baseline to 5.5 years after enrollment."; 2033-03-01
NCT07784608
"A Clinical Trial to Evaluate the Drug-drug Interactions of Co-administered 'HUC2-744-A' and 'HUC2-744-B' in Healthy Adult Volunteers"; n 28; "AUCτ"; 2027-11
recorded 2026-09-01 · last checked 2026-09-04
Q9
Which running trial of Telmisartan could settle lifespan?
NCT02735707 measures All-cause mortality, reading out 2028-02.
2 open trials; n 20000; "Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia"
Show the evidence
Trial
NCT02735707
"Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia"; n 20000; "All-cause mortality"; 2028-02
NCT06815497
"Telmisartan in Combination With Cytotoxic Regimens in Platinum-Resistant Ovarian Cancer"; n 33; "Progression free survival"; 2029-05-14
Q10
Which 62 trials of Telmisartan posted no result?
Posted no result
62 of 62 completed trials
Registrations
NCT00274612, NCT00274118, NCT00274144, NCT00240422, NCT00153049 and NCT00490958, and 56 more
Completion dates
oldest 2003-11; newest 2023-06-30
Show the evidence
Trial
NCT00274612
2003-11
NCT00274118
2004-01
NCT00274144
2004-05
NCT00240422
2004-07
NCT00153049
2005-06
NCT00490958
2005-06
14 further recorded trials
NCT00144222
2005-08
NCT00153088
2005-11
NCT00153023
2005-12
NCT00407862
2006-06
NCT00257491
2006-08
NCT00146341
2006-09
NCT00316095
2007-08
NCT00326768
2007-08
NCT00926341
2008-09
NCT00421863
2009-01
NCT00538486
2009-06
NCT00750113
2009-08
NCT00560430
2009-10
NCT00452192
2009-12
Q11
At the median, Telmisartan's trials enrolled 180 people — anything larger?
Median enrolment
180
Largest enrolment
1165781
Registered trials counted
193
Q12
What do 1568 spontaneous reports say about Telmisartan — and not say?
These are reports people sent to a regulator. They do not show the medicine caused the reaction. Nobody counted how many people took the medicine and reported nothing. The same event can be reported more than once, and many reports are incomplete. News coverage, lawsuits and new warnings change how often people report. A count is not a rate and not a risk.
Telmisartan appears in spontaneous reports to regulators. Across the 10 most-reported reaction terms, 1568 reaction mentions were counted: hypotension 233; hyponatraemia 219; acute kidney injury 168; hypertension 165. open-targets-adr · CHEMBL1017 · 2026-06-24
Show the evidence
hypotension
233
hyponatraemia
219
acute kidney injury
168
hypertension
165
blood pressure increased
162
hyperkalaemia
159
4 more recorded rows
loss of consciousness
129
renal failure acute
129
renal failure
111
suicide attempt
93
recorded 2026-06-24 · last checked 2026-09-04
Q13
Telmisartan and CYP2C19: shared by which compounds?
CYP2C19 appear in Telmisartan's recorded interaction sentences, 2 in all. openfda-label+europepmc · 2026-08-30
Interpretation pharmacokinetics
Show the evidence
CYP2C19
pharmacokinetics
Telmisartan is not expected to interact with drugs that inhibit cytochrome P450 enzymes; it is also not expected to interact with drugs metabolized by cytochrome P450 enzymes, except for possible inhibition of the metabolism of drugs metabolized by CYP2C19.
pharmacokinetics
Telmisartan is not metabolized by the cytochrome P450 system and had no effects in vitro on cytochrome P450 enzymes, except for some inhibition of CYP2C19.
recorded 2026-08-30 · last checked 2026-09-04
Q14
Was Telmisartan studied with fasting and exercise?
fasting and exercise are named in Telmisartan's label sentences: "There were no significant differences between the two groups in week 12 changes for HOMA-IR or fasting triglycerides (- 0.18 ± 1.24 vs 0.39 ± 1.39, p = 0.181; - 26 ± 76 vs - 10 ± 81 mg/dL, p = 0.679, respectively) (telmisartan vs placebo)." openfda-label+europepmc · 2026-08-30
2 recorded statements; fasting, exercise
Show the evidence
fasting
There were no significant differences between the two groups in week 12 changes for HOMA-IR or fasting triglycerides (- 0.18 ± 1.24 vs 0.39 ± 1.39, p = 0.181; - 26 ± 76 vs - 10 ± 81 mg/dL, p = 0.679, respectively) (telmisartan vs placebo).
exercise
In people with peripheral artery disease (PAD), the Telmisartan Plus Exercise to Improve Functioning in Peripheral Artery Disease (TELEX) randomized clinical trial tested whether telmisartan (TEL), with or without exercise, significantly improved 6-minute walk distance at 6-month follow-up, compared with placebo (PLA).
recorded 2026-08-30 · last checked 2026-09-04
Q15
What is recorded about Telmisartan and AMPK?
"This study aimed to delineate the cardioprotective mechanisms of low-dose Telmisartan against myocardial ischemia/reperfusion (I/R) injury, specifically by distinguishing between AMPK-dependent and AMPK-independent pathways using AMPK kinase-dead (KD) mouse models." — where Telmisartan and AMPK appear together. Europe PMC · pathway abstract search · 2026-03-19
"This study aimed to delineate the cardioprotective mechanisms of low-dose Telmisartan against myocardial ischemia/reperfusion (I/R) injury, specifically by distinguishing between AMPK-dependent and AMPK-independent pathways using AMPK kinase-dead (KD) mouse models."
PMID 41864588
"Consistently, Telmisartan activated AMPK, phosphorylated cTnI(Ser150), PGC-1α, and increased the Bcl-2/Bax ratio in WT but not KD mice, whereas LKB1 activation occurred independently of AMPK."
PMID 41864588
"Low-dose Telmisartan confers cardioprotection against I/R injury via dual mechanisms: it primarily utilizes AMPK-dependent signaling to combat oxidative stress, apoptosis, and infarction, while independently of AMPK, it preserves calcium homeostasis and activates LKB1."
autophagyPMID 40935114
"Key targets included Signal Transducer and Activator of Transcription 3 (STAT3), B-cell lymphoma 2 (Bcl2), and Nuclear Factor kappa-light-chain-enhancer of activated B cells (NF-κB), regulators of cellular autophagy, suggesting telmisartan's potential interaction with autophagy-related pathways."
mTOR
PMID 32893519
"Telmisartan decreased VSMC proliferation, which was accompanied by decreased phosphorylations of mammalian target of rapamycin (mTOR) at Ser2448 (p-mTOR-Ser<sup>2448</sup>) and p70 S6 kinase (p70S6K) at Thr389 (p-p70S6K-Thr<sup>389</sup>) in dose- and time-dependent manners."
PMID 32893519
"Co-treatment with compound C, a specific AMPK inhibitor, or ectopic expression of the dn-AMPKα1 gene, significantly reversed telmisartan-inhibited VSMC proliferation, p-mTOR-Ser<sup>2448</sup> and p-p70S6K-Thr<sup>389</sup> levels."
PMID 32893519
"Finally, telmisartan also exhibited inhibitory effects on VSMC proliferation by increasing p-AMPK-Thr<sup>172</sup> and decreasing p-mTOR-Ser<sup>2448</sup> and p-p70S6K-Thr<sup>389</sup> in a PDGF-induced in vitro atherosclerosis model."
autophagy
PMID 38783939
"The findings suggest the protective efficiency of telmisartan and nano Sp extract against cardiotoxicity via activations of the antioxidant, antiapoptotic, and autophagy signaling pathways."
PMID 25249228
"In conclusion, this study provides evidence that the chronic pharmacological activation of the PPARγ-mediated autophagy pathway using telmisartan may represent a promising therapeutic strategy for atherosclerosis."
sirtuinPMID 23137106
"Telmisartan has been reported to function as a partial agonist of the peroxisome proliferator-activated receptor (PPAR) γ, which is also targeted by the nicotinamide adenine dinucleotide (NAD)-dependent deacetylase (SIRT1)."
NAD+PMID 23137106
"Telmisartan has been reported to function as a partial agonist of the peroxisome proliferator-activated receptor (PPAR) γ, which is also targeted by the nicotinamide adenine dinucleotide (NAD)-dependent deacetylase (SIRT1)."
sirtuinPMID 23137106
"Our results indicate that telmisartan acts through a PPARγ-independent pathway, but at least partially exerts its effects by acting directly on skeletal muscle AMPK/SIRT1 pathways."
NAD+
PMID 22890154
"Conversely, cotreatment with telmisartan inhibited both NAD(P)H oxidase activity and production of ROS."
PMID 22890154
"These findings suggest that glomerular injury resulting from FK506 is caused by oxidative stress mediated by activation of NAD(P)H oxidase and that telmisartan exerts a renoprotective effect via antioxidative activity."
recorded 2026-03-19 · last checked 2026-09-04
Where it is registeredIdentifiers, relations and other names
ChEMBL ATC CC BY-SA · ClinicalTrials.gov — US Government work · Europe PMC — metadata only, under the recorded legal gate · Open Targets 26.06 — CC0 · derived from this page's own recorded fields; no external licence · mixed register set; per-register licences in docs/specs/corpus-20k-sources.md · openFDA / DailyMed — US Government work
✗ required summary fields resolved: 5 required field(s) not terminal: Why people use it, Best-supported result, Most important common problem, Biggest unanswered question, Human evidence
✓ public claims reviewed: 0 reviewed claim(s); drafts are never rendered
✓ source coverage passed: 11 source rows
✓ no critical contamination: no quarantine open
✓ canonical metadata passed: slug and display name present
✓ no raw internal fields: enforced by the copy-contract test over the rendered page
This is a record of evidence. It is not medical advice, and it does not say this substance suits you. Nothing here says any substance on RNAWiki is appropriate for a child.